Synergy CHC Corp.

Listed Company

SNYRCIK 0001562733NasdaqNon-AcceleratedSmaller ReportingMedicinal Chemicals & Botanical ProductsNevadaFY ends Dec 31

Period

FY 2025

Revenue

$30.38M

Net Income

$-12.34M

Total Assets

$10.16M

Equity

$-23.13M

Shares Out

11.30M

Op. Cash Flow

$-2.59M

Business

Synergy CHC Corp. is a provider of consumer health care, beauty, and lifestyle products focused on brand management, marketing, product development and distribution. Its main offerings include the FOCUSfactor brain health supplements and RTD energy beverages, Flat Tummy nutritional and lifestyle products (teas, shakes, supplements, apparel and an app), and six developing non-core brands across beauty, hand care, lingerie, neuropathic pain and OTC categories. Key business divisions center on its marquee brands (FOCUSfactor and Flat Tummy) alongside developing brands. Products are sold through major U.S. retailers and club stores, direct-to-consumer websites and apps, and selected international markets including Canada and the United Kingdom.

Summary from filing dated 2025-03-31

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	30	35	43	—	—
Cost of sales	10	11	—	—	—
Gross Profit	20	24	32	20	23
Selling and marketing	13	13	15	11	18
General and administrative	9	5	6	5	7
Reserve for bad debts	7	—	—	283,971	69,070
Depreciation and amortization	133,334	133,334	33,333	1	2
Total operating expenses	29	18	21	28	28
(Loss) Income from operations	−8	6	11	−8	−5
Other income	—	−510,534	—	—	—
Interest income	−15,065	−1,523	−1,616	—	—
Interest expense	6	4	4	—	—
Gain on settlement of notes payable	−2	—	—	—	—
Remeasurement loss (gain) on translation of foreign subsidiary	14,833	−18,954	−1,517	—	—
Total other expenses	4	4	4	1	1
Net (loss) income before income taxes	−12	2	7	−9	−6
Income tax expense	117,471	102,085	234,980	−131,537	247,694
Net (loss) income	−12	2	6	−9	−6
Net (loss) income per share basic (in Dollars per share)	−1.27	0.28	0.86	—	—
Net (loss) income per share - diluted (in Dollars per share)	−1.27	0.28	0.86	—	—
Basic (in Shares)	10	8	7	—	—
Diluted (in Shares)	10	8	7	—	—
Foreign currency translation adjustment	−106,504	54,690	—	—	—
Comprehensive (loss) income	−12	2	6	−9	−6

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2019 2019-12-31
Cash and cash equivalents	3	687,920	632,534	—	1
Restricted cash	100,000	100,000	100,000	—	—
Accounts receivable, net	3	5	2	—	1
Other receivables, net	—	2	—	—	—
Prepaid expenses (including related party amount of $110,803 and $312,966, respectively)	351,049	2	797,985	—	186,143
Inventory, net	4	2	4	—	2
Total Current Assets	10	16	12	—	5
Intangible assets, net	150,000	283,333	416,667	—	7,636
Total Assets	10	16	12	—	5
Accounts payable and accrued liabilities (including payable to shareholder of $196,934 and $88,644, respectively)	6	5	12	—	5
Income taxes payable	88,108	242,977	185,665	—	—
Contract liabilities	1,526	24,252	14,202	5,197	—
Short term loans payable, net of debt discount, related party	100,000	—	—	—	—
Short term loans payable, net of debt discount	—	8	2	—	—
Current portion of notes payable, net of debt discount	2	—	—	—	—
Current portion of long-term notes payable, net of debt discount and debt issuance cost, shareholder	—	4	—	—	—
Total Current Liabilities	8	17	14	—	10
Notes payable, net of debt discount, shareholder	—	8	—	—	—
Notes payable, net of debt discount	25	7	13	—	—
Total long-term liabilities	25	16	26	—	246,916
Total Liabilities	33	33	40	—	10
Commitments and contingencies (Note 13)	—	—	—	—	—
Common stock, $0.00001 par value; 300,000,000 shares authorized; 11,483,926 and 8,721,818, shares issued, respectively; 11,303,853 and 8,541,745 outstanding, respectively	114	87	76	—	899
Additional paid in capital	34	28	19	—	19
Accumulated other comprehensive loss	−154,281	−47,777	−102,467	—	11,364
Accumulated deficit	−56	−44	−46	—	−24
Less: Treasury stock (180,073 shares) at cost	−127,500	−127,500	−127,500	—	—
Total stockholders deficit	−23	−17	−27	−34	−5
Total Liabilities and Stockholders Deficit	10	16	12	—	5

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Amortization of debt discount and debt issuance cost	2	56,796	48,610	—	—
Stock based compensation	136,247	—	—	201,155	440,999
Stock issued for modification of notes payable	847,062	—	—	—	—
Stock issued for services	127,200	—	—	—	—
Foreign currency transaction (gain) loss	5,531	54,321	−105,192	−1,308	131,868
Remeasurement gain on translation of foreign subsidiary	14,833	−18,954	—	—	—
Non cash implied interest	—	4,799	29,401	—	—
Bad debts	2	—	—	283,972	69,070
Bad debt, related party	4	—	—	—	—
Write-off of inventory	894,341	125,364	251,021	257,111	1
Stock issued for loan financing	—	97,920	—	—	—
Income from employee retention credits	—	−252,405	—	—	—
Income from insurance on stolen goods	—	−258,129	—	—	—
Accounts receivable	2	−3	1	3	−193,687
Other receivables	345,388	−1	—	—	—
Loan receivable, related party	—	84,937	−51,245	—	—
Inventory	−3	2	4	552,158	−884,141
Prepaid expenses	1	−1	−288,789	642,704	314,404
Prepaid expense, related party	202,163	−145,092	−369,427	—	—
Income taxes payable	−84,271	57,312	185,665	—	—
Contract liabilities	−22,726	10,050	9,005	−41,823	46,652
Accounts payable and accrued liabilities	622,099	−3	−7	−3	2
Accounts payable, related party	489,093	61,759	156,759	−819,179	898,029
Net cash used in operating activities	−3	−5	421,729	3	1
Cash Flows from Investing Activities	—	—	—	—	−198,007
Proceeds from issuance of common stock at IPO	—	8	—	—	—
Proceeds from issuing common stock	4	—	—	—	—
Advances from related party	235,000	4	—	324,102	—
Repayments of advances to related party	−135,000	−3	−1	−324,102	—
Repayment of notes payable, shareholder	−10	−84,500	—	—	—
Proceeds from notes payable	21	1	360,000	—	—
Payment of loan financing fees	−2	—	—	—	—
Repayment of notes payable	−8	−5	−2	−2	−3
Net cash provided by financing activities	5	5	−2	−2	−3
Effect of exchange rate on cash, cash equivalents and restricted cash	−135,249	54,690	—	−167,752	257,106
Net increase in cash, cash equivalents and restricted cash	2	55,386	−2	728,598	−1
Interest	3	4	4	939,711	1
Income taxes	147,377	—	—	—	—
Accounts payable converted to loan payable upon settlement	—	4	—	—	—
Reduction of short term related party note payable by reduction of prepaid balance	—	328,003	—	—	—
Issuance of common stock for loan financing	220,869	—	—	—	—
Issuance of pre-funded warrants for settlement of shareholder notes payable	899,993	—	—	—	—
Exercise of pre-funded warrants	4	—	—	—	—
Loan fees payable to lender	375,000	—	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro